metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)
versus everolimus
	nivolumab alone vs. everolimus	1	none	inconclusive results for: deaths (OS) (extension); progression or deaths (PFS); DOR; DOR (extension); objective responses (ORR) (extension); TRAE leading to death (grade 5); Cough TRAE (grade 3-4); Decreased appetite TRAE (grade 3-4); Diarrhoea TRAE (grade 3-4); Dysgeusia TRAE (grade 3-4); Dyspnoea TRAE (grade 3-4); Epistaxis TRAE (grade 3-4); Fatigue TRAE (grade 3-4); Nausea TRAE (grade 3-4); Peripheral oedema TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Pruritus TRAE (grade 3-4); Rash TRAE (grade 3-4)	statistically conclusive 27 % decrease in deaths (OS) but the degree if certainty is unassessable statistically conclusive 6.0-fold increase in objective responses (ORR) but the degree if certainty is unassessable suggested 50 % decrease in TRAE (any grade) but the degree if certainty is unassessable suggested 60 % decrease in TRAE (grade 3-4) but the degree if certainty is unassessable suggested 45 % decrease in TRAE leading to discontinuation (any grade) but the degree if certainty is unassessable suggested 79 % decrease in Anaemia TRAE (grade 3-4) but the degree if certainty is unassessable suggested 96 % decrease in Mucosal inflammation TRAE (grade 3-4) but the degree if certainty is unassessable suggested 97 % decrease in Stomatitis TRAE (grade 3-4) but the degree if certainty is unassessable	-

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus everolimus